Can an NAD+ booster protect muscle on semaglutide?

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Sironax is about halfway to its enrollment target in a Phase 2 trial of an oral NAMPT activator for adults with obesity.

Weight-loss drugs come with a side story that gets less attention than the number on the scale. Some of the weight loss is muscle. Sironax is now testing a pill designed to tackle that.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3579

Sironax

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Sironax is a clinical-stage biotechnology company founded in 2017 that develops small-molecule therapeutics targeting fundamental mechanisms of aging and age-related degeneration. The company's pipeline focuses on modulating dysregulated cellular death pathways, energy homeostasis, and inflammatory signaling through inhibitors of SARM1, RIPK1, and activators of NAMPT, with applications in neurodegenerative, metabolic, and inflammatory diseases. Sironax operates globally with offices in the United States, China, Switzerland, and Australia, and has established a proprietary Brain Delivery Module platform for enhanced blood-brain barrier penetration of therapeutic payloads.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE